Monitor the Q2 2026 10-Q for actual revenue figures. The new Giant Food pilot, fire department programs, and MCED legislation progress are non-financial catalysts with potential long-term impact, but near-term revenue visibility remains low.
Price Chart
Executive Summary
20/20 Biolabs filed an 8-K furnishing an investor presentation (August 2026) covering commercial updates, a new pilot with Giant Food for its OneTest for Longevity, and CEO's East Asia trip. The presentation contains forward-looking statements on MCED reimbursement legislation and revenue growth, but no hard financial figures were disclosed. The filing is a routine business update with no material financial impact.
Key Facts
- Q2 2026 generated the company's best quarterly cancer testing revenue to date (preliminary, unaudited).
- 29 orders from new accounts including occupational health, fire departments, and primary care physicians.
- Maryland Firefighter Cancer Screening Program: 18 fire departments with 1,400+ participants.
- Selected for Vermont Firefighter Cancer Screening Program (up to 4,500 firefighters, starting Q3 2026).
- New pilot with Giant Food for OneTest for Longevity – 3-month pilot starting August 2026.
- CEO Jonathan Cohen completed a two-week East Asia trip (Taipei, Tokyo, Seoul) targeting commercial expansion, real-world data, and M&A opportunities.
- The presentation highlights the Multi-Cancer Early Detection Screening Coverage Act (passed Feb 3, 2026) as a potential growth catalyst for MCED tests like OneTest.
- Revenue projections and royalty pool sharing included, but are based on hypothetical assumptions and forward-looking statements.
Financial Impact
No specific dollar amounts reported; Q2 2026 revenue preliminarily described as best quarterly cancer testing revenue to date. Revenue projections on Slide 13 are hypothetical and not guarantees.
Risk Factors
- FDA authorization and CMS reimbursement for OneTest are not guaranteed.
- Competition from Grail (Galleri) and Exact Sciences (Cologuard) could limit market adoption.
- Revenue projections are based on a single-company analogy and may not be achieved.
- Forward-looking statements subject to significant uncertainty.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-085514 |
| Document: ea030072601ex99-1.htm | 0001213900-26-085514 |
| Document: 0001213900-26-085514-index-headers.html | 0001213900-26-085514 |
| Document: 0001213900-26-085514-index.html | 0001213900-26-085514 |
| Document: 0001213900-26-085514.txt | 0001213900-26-085514 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Oct 21, 2026 4d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Aug 17, 2026 9w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2400 (−53.85%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2400 (−56.39%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2400 (−45.62%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2400 (−60.62%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2400 (+57.66%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2400 (−75.26%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers